In a dramatic turn of events, Health Secretary Robert F. Kennedy Jr. confronts CDC Director Susan Monarez, demanding she fire agency officials or face termination herself. The standoff has paralyzed the CDC amid ongoing turmoil.
As RFK Jr. winds down mRNA vaccine research, experts warn America may lose its edge in vaccine development, putting public health at risk and ceding ground to adversaries like China.
NIH Director Jay Bhattacharya reveals that millions in mRNA research contracts were canceled due to public distrust. He argues that without credibility, mRNA technology can't serve its health mission.
The NIH's Jay Bhattacharya argues that public distrust led to the cancellation of mRNA vaccine contracts. This statement contrasts with Health Secretary Kennedy's claims about vaccine safety and efficacy.
Dr. Vinay Prasad is back at the FDA's Center for Biologics Evaluation and Research, raising eyebrows after being ousted amid political turmoil and criticism. His return ignites debates about drug approvals and public health leadership under the Trump administration.
In a surprising move, U.S. health officials have canceled $500 million in mRNA vaccine research, citing studies that question their safety and effectiveness. Critics warn this decision undermines vital public health advancements made during the pandemic.
The U.S. Senate has confirmed Susan Monarez as the new CDC director, a decision that raises questions amid ongoing debates about vaccines, public health, and the influence of Robert F. Kennedy Jr. on health policies.
In a controversial move, US Health Secretary Robert F. Kennedy Jr. mandates the removal of thimerosal from vaccines, aiming to protect vulnerable populations from mercury exposure, despite longstanding evidence of its safety.
In a surprising move, Health Secretary Robert F. Kennedy Jr. has dismissed two senior deputies, marking a significant leadership change at the Department of Health and Human Services. This decision reflects Kennedy's strategic vision for the agency's future.
In a surprising move, the Trump administration has expanded RSV vaccinations to adults starting at age 50. This decision follows the advice of a recently dismissed government panel and raises questions about public health policies.
